Cytosorbents Corp SEC Filings

CytoSorbents director Edward R. Jones reported a change in beneficial ownership showing a disposition of 88,834 shares of Common Stock on 08/08/2025. The filing states that the 88,834 shares comprise 69,300 Restricted Stock Units (grants from 2015, 2016, 2017 and 2018 that vest on a defined "Change In Control") and 19,534 shares owned outright by the reporting person. The filing also shows an acquisition of 22,000 stock options granted under the company plan with a $1 exercise price; those options vest in four equal quarterly installments over one year following grant and appear to expire on 08/08/2035. The Form 4 was submitted as a single reporting person filing and includes a Power of Attorney exhibit.

Michael G. Bator, a director of Cytosorbents Corporation (CTSO), reported a transaction dated 08/08/2025 in which he disposed of 151,273 shares of common stock and was granted stock options to purchase 44,000 shares at an exercise price of $1. The 151,273 shares reported include 3,300 RSUs (granted 03/15/2018), 6,000 RSUs (02/24/2017), 60,000 RSUs (06/07/2016) that vest upon a Change of Control, and 81,973 shares owned outright by the reporting person. The options were granted under the CytoSorbents 2014 Long-Term Incentive Plan and vest in four equal quarterly installments over one year, subject to continued service, with an expiration indicated as 08/08/2035.

Peter J. Mariani, Chief Financial Officer of Cytosorbents Corp. (CTSO), reported insider awards and holdings dated 08/08/2025. The filing shows an acquisition of 71,500 shares of Common Stock represented by restricted stock units (RSUs) at a reported price of $0. The report also discloses a grant of 90,000 stock options with an exercise/conversion price of $1 and an expiration reference of 08/08/2035. Option vesting is described in the filing.

The filing lists total common stock beneficially owned following the reported transaction as 538,113 shares and details additional RSU awards: 110,000, 65,000, and 175,000 subject to various vesting conditions, plus 116,613 shares owned by the reporting person. Vesting schedules for the RSUs and the options are specified in the footnotes.

Insider reported: Director Jiny Kim disclosed changes in beneficial ownership of Cytosorbents Corporation (CTSO). The Form 4 shows a reported disposition of 77,819 shares of Common Stock and an acquisition of 22,000 stock options with a $1 exercise price. The options were granted under the companys long-term incentive plan and will vest in four equal quarterly installments over one year following the grant, subject to continued service.

The 77,819 figure includes 69,300 RSUs that convert to shares only upon a defined change in control and 8,519 shares directly owned by the reporting person. The filing was signed by an attorney-in-fact and references a power of attorney exhibit.

Insider equity awards and holdings reported for Cytosorbents (CTSO). Officer Vincent Capponi was granted 89,100 restricted stock units (RSUs) and a stock option award for 111,100 shares on 08/08/2025. The RSUs vest in equal parts at the first and second anniversaries of the grant and certain RSUs will settle into common stock upon a defined Change in Control. The stock options vest over three years (one-half at year one, one-fourth at year two, one-fourth at year three) and have a stated exercise price of $1 with an expiration in 2035.

Following these reported transactions and the listed previously outstanding awards and shares, the reporting person’s beneficial ownership is shown as 766,268 shares of common stock (direct).

Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corporation (CTSO), was granted equity awards on 08/08/2025. The filing reports an award of 70,000 restricted stock units (RSUs) that vest in equal parts on the first and second anniversaries of the grant, and a grant of 95,000 stock options with an exercise price of $1 that vest one-half on the first anniversary, one-fourth on the second and one-fourth on the third anniversary of the grant.

The disclosure shows these RSUs will settle into common stock upon vesting and notes certain RSUs that vest on a Change In Control (120,000 and 55,000 RSUs). Following the reported transactions, the reporting person beneficially owns 473,025 shares (direct). All information is taken from the Form 4 filing text.

Alan D. Sobel, a director of Cytosorbents Corp (CTSO), reported a substantial disposition and new option grant. The filing shows a disposal of 145,757 shares of Common Stock on 08/08/2025. That disposed amount comprises 69,300 RSUs (grants from 2015–2018 that settle into shares upon a Change in Control) and 76,457 shares owned directly by the reporting person.

Separately, Sobel was granted 22,000 stock options at a $1 exercise price on 08/08/2025; those options vest in four equal quarterly installments over one year and expire on 08/08/2035. The report also notes 2,000 shares held indirectly in the Bernard Sobel Revocable Trust for which he is trustee and beneficiary.

CytoSorbents Corporation (Nasdaq: CTSO) filed a Form 8-K on June 24, 2025 to disclose a material regulatory development. Under Item 8.01 – Other Events, the company reported that it has decided to appeal the U.S. Food & Drug Administration’s (FDA) denial letter related to its De Novo request for DrugSorb-ATR, a blood purification device designed to remove antithrombotic agents during cardiothoracic surgery. The filing furnishes a press release (Exhibit 99.1) as additional detail; however, that release is not included in the body of the 8-K.

The appeal process indicates that management believes there are sufficient grounds to contest the FDA’s decision, but the 8-K offers no timetable, data, or probability of success. No sales, earnings, or forecast information is provided, and no other corporate actions (financing, partnerships, leadership changes) are mentioned. Investors should note that DrugSorb-ATR represents an important U.S. commercial opportunity for CTSO, but the denial—now under appeal—introduces regulatory uncertainty and potential delays to market entry.